An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112
NCT02107846
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
10
Enrollment
INDUSTRY
Sponsor class
Conditions
Gaucher Disease
Interventions
DRUG:
PRX-112
Sponsor
Protalix